Aptose Biosciences Secures $10M Loan From Hanmi Pharmaceutical For Tuspetinib Development; Companies To Negotiate New Co-Development Agreement For AML Treatment
Aptose Biosciences Secures $10M Loan From Hanmi Pharmaceutical For Tuspetinib Development; Companies To Negotiate New Co-Development Agreement For AML Treatment
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), today announced that it received a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co. Ltd. ("Hanmi"). The loan is convertible as prepayment of milestone obligations under the Future Collaboration Agreement (as defined hereinafter) or repayable after the expected completion of a triple drug combination trial with tuspetinib in newly diagnosed AML patients. Aptose will use the proceeds from such loan for the development of tuspetinib.
Aptose Biosciences Inc.（"Aptose"或"公司"）（纳斯达克: APTO, TSX: APS），一家临床阶段的精准肿瘤药物公司，正在研发tuspetinib，这是一种高度差异化的口服激酶抑制剂，用于治疗急性髓性白血病（AML）患者。公司今天宣布，通过与韩美药品股份有限公司（"韩美"）的《未来合作协议及后续贷款协议》，获得了1000万美元的贷款。该贷款可转换为预付根据未来合作协议（如下文所定义）的里程碑义务，或在tuspetinib与新诊断AML患者进行三联药物组合试验后偿还。Aptose将利用此类贷款的收入用于tuspetinib的开发。
Beyond the $10 million Facility Agreement, Aptose and Hanmi have agreed to negotiate a new tuspetinib co-development collaboration agreement (the "Future Collaboration Agreement'), intended to provide additional funding to accelerate clinical development of tuspetinib. Aptose licensed tuspetinib from Hanmi Pharmaceutical in November 2021.
1000万美元贷款外，Aptose与花旗药业还同意协商一项新的tuspetinib协同开发协议（"未来合作协议"），旨在提供额外的资金加速tuspetinib的临床开发。Aptose于2021年11月从Hanmi药业获得了tuspetinib的许可。
